[Bi-Profenid in rheumatologic practice].
Sixty-six patients managed in an outpatient clinic for various inflammatory or degenerative conditions were given 300 mg per day of Bi-Profenid in two daily doses of one 150 mg tablet each, for 20 days. At completion of the trial, patients with degenerative disease showed a statistically significant improvement in pain upon mobilization, nocturnal pain and pain index as evaluated by the pain scale. Similarly, in patients with inflammatory conditions, significant effectiveness was recorded upon nocturnal pain, overall pain as assessed by the pain scale and articular index. Tolerance was considered satisfactory in more than 65% of cases. The most common undesirable side-effect was gastric pain (22.7%). Bi-Profenid thus confirms its effectiveness in pain due to arthrosis as well as in inflammatory conditions.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007660:Ketoprofen / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010666:Phenylpropionates / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013607:Tablets
D003692:Delayed-Action Preparations; D010666:Phenylpropionates; D013607:Tablets; D007660:Ketoprofen
Etude du Bi-Profénid en pratique rhumatologique.